îæ€çŽ¢
îæ€çŽ¢
î
Neurosense Therapeutics Ltd
NRSNWîãŠã©ãããªã¹ãã«è¿œå
0.190USD
+0.050+35.71%
çµå€Â 05/15, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
0.00æ䟡ç·é¡
--çŽè¿12ã¶æPER
î
詳现ãã£ãŒãã衚瀺
Intraday
1m
30m
1h
D
W
M
D
æ¬æ¥
+35.71%
5æ¥é
+11.76%
1ã¶æ
+18.75%
6ã¶æ
-34.44%
幎åæ¥
-38.71%
1幎é
-23.97%
TradingKey æ ªåŒã¹ã³ã¢
ããŒã¿ãäžååãªãããæ ªåŒã¹ã³ã¢ã¯å©çšã§ããŸããã
Neurosense Therapeutics Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
財åææšî
EPS
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Neurosense Therapeutics Ltdã®äŒæ¥æ å ±î
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
äŒæ¥ã³ãŒãNRSNW
äŒæ¥åNeurosense Therapeutics Ltd
æé«çµå¶è²¬ä»»è
ãCEOãMr. Alon Ben-Noon
ãŠã§ããµã€ãhttps://www.neurosense-tx.com/
人æ°éæ
102.160
+3.297Â (+3.33%)
300.230
+2.020Â (+0.68%)
225.320
-10.420Â (-4.42%)
4538.710
-111.520Â (-2.40%)
482.020
-7.101Â (-1.45%)
1407.610
+24.890Â (+1.80%)
724.660
-51.350Â (-6.62%)
396.780
-4.290Â (-1.07%)
78087.440
-143.560Â (-0.18%)
422.240
-21.060Â (-4.75%)
